Table 1.
Correlation of TRIM21 expression and clinical features of patients with breast cancer
| Variable | Cases (n) | TRIM21
|
P-valuea | |
|---|---|---|---|---|
| Low expression | High expression | |||
| Tumor size (cm) | 0.016 | |||
| ≤3 | 75 | 26 (34.7%) | 49 (65.3%) | |
| >3 | 94 | 50 (53.2%) | 44 (46.8%) | |
| LN metastasis | 0.341 | |||
| No | 69 | 28 (40.6%) | 41 (59.4%) | |
| Yes | 100 | 48 (48.0%) | 52 (52.0%) | |
| ER | 0.003 | |||
| Negative | 90 | 50 (55.6%) | 40 (44.4%) | |
| Positive | 79 | 26 (32.9%) | 53 (67.1%) | |
| PR | 0.069 | |||
| Negative | 87 | 45 (51.7%) | 42 (48.3%) | |
| Positive | 82 | 31 (37.8%) | 51 (62.2%) | |
| Her2 | 0.005 | |||
| Negative | 138 | 55 (39.9%) | 83 (60.1%) | |
| Positive | 31 | 21 (67.7%) | 10 (32.3%) | |
| Ki67 | 0.659 | |||
| Negative | 81 | 35 (43.2%) | 46 (56.8%) | |
| Positive | 88 | 41 (46.6%) | 47 (53.4%) | |
| Histologic grade | 0.073 | |||
| I | 16 | 4 (25.0%) | 12 (75.0%) | |
| II | 107 | 46 (43.0%) | 61 (57.0%) | |
| III | 46 | 26 (56.5%) | 20 (43.5%) | |
| Clinical stage | 0.001 | |||
| I | 67 | 37 (55.2%) | 30 (44.8%) | |
| II | 87 | 28 (32.2%) | 59 (67.8%) | |
| III | 15 | 11 (73.3%) | 4 (26.7%) | |
Note:
a
Chi-square test.
Abbreviations: ER, estrogen receptor; Her2, human epidermal growth factor receptor 2; LN, lymph node; PR, progesterone receptor; TRIM21, tripartite motif- containing protein 21.